Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation

Teri L Malo, Megan E Hall, Noel T Brewer, Christine R Lathren, Melissa B Gilkey, Teri L Malo, Megan E Hall, Noel T Brewer, Christine R Lathren, Melissa B Gilkey

Abstract

Background: Improving healthcare providers' communication about HPV vaccination is critical to increasing uptake. We previously demonstrated that training providers to use presumptive announcements to introduce HPV vaccination improved uptake, whereas training them to use participatory conversations had no effect. To understand how communication training changed provider perceptions and communication practices, we evaluated intermediate outcomes and process measures from our randomized clinical trial, with a particular focus on identifying mechanisms that might explain the announcement training's impact.

Methods: In 2015, a physician educator delivered 1-h in-clinic HPV vaccination recommendation trainings at 20 primary care clinics in North Carolina serving 11,578 patients age 11 or 12. Clinics were randomized to receive training to use "announcements" that presume parents are ready to vaccinate or "conversations" that invite dialog about vaccination. Training participants were 83 HPV vaccine providers. Pre- and post-training surveys assessed constructs from the theory of planned behavior (TPB), including providers' attitudes and subjective norms about HPV vaccination and their perceived behavioral control to recommend HPV vaccination. Surveys also assessed providers' perceptions of the announcement and conversation communication strategies.

Results: Both trainings improved TPB-related constructs, including providers' positive attitudes toward HPV vaccination, subjective norms, and perceived behavioral control to recommend the vaccine (all p < .001, Cohen's d = .62-.90). Furthermore, in both trainings, the amount of time providers reported needing to discuss HPV vaccination with parents decreased from pre-training to 1-month follow-up (mean = 3.8 vs. 3.2 min, p = .01, d = .28). However, announcement trainings outperformed conversation trainings on other measures. For example, providers who received announcement training more often reported that the communication strategy saved them time, was easy to use, helped them promote HPV vaccination as routine care, and increased HPV vaccination coverage in their clinics (all p < .05; d = .44-.60).

Conclusions: Both announcement and conversation trainings improved providers' HPV vaccine-related perceptions. However, providers viewed announcements as easier to use and more effective, which may help to explain the success of this training approach. Future provider communication interventions should consider implementation outcomes, including acceptability, alongside more traditional TPB constructs.

Trial registration: clinicaltrials.gov, NCT02377843 . Registered on February 27, 2015.

Keywords: Adolescent health; Cancer; Health communication; Healthcare providers; Human papillomavirus vaccines; Process assessment.

Conflict of interest statement

Ethics approval and consent to participate

The University of North Carolina Institutional Review Board approved the trial protocol (IRB #14-1873). Immediately preceding the training session, research staff disseminated study fact sheets to participants. The IRB granted a waiver of written documentation of informed consent.

Consent for publication

Not applicable.

Competing interests

N.T. Brewer has received research grants from Merck and Pfizer and has served on a paid advisory board for Merck. The remaining authors (TM, MH, CL, MG) declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Frequency of using announcement and conversation recommendation strategies (n = 83)
Fig. 2
Fig. 2
Time it takes to discuss adolescent vaccines (n = 83)
Fig. 3
Fig. 3
Increases in HPV vaccination attitudes, subjective norms, and perceived behavioral control (n = 83)

References

    1. Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother. 2016;12:1332–1342. doi: 10.1080/21645515.2015.1108500.
    1. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519–527. doi: 10.1093/cid/ciw354.
    1. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP) MMWR Recomm Rep. 2014;63:1–30.
    1. U.S. Food and Drug Administration . Prescribing information [package insert]. Gardasil 9 [human papillomavirus 9-valent vaccine, recombinant] Silver Spring: US Department of Health and Human Services, Food and Drug Administration; 2016.
    1. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination— updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405–1408. doi: 10.15585/mmwr.mm6549a5.
    1. Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Curtis CR, MacNeil J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:850–858. doi: 10.15585/mmwr.mm6533a4.
    1. Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol Biomark Prev. 2015;24:1673–1679. doi: 10.1158/1055-9965.EPI-15-0326.
    1. Gilkey MB, McRee AL. Provider communication about HPV vaccination: a systematic review. Hum Vaccin Immunother. 2016;12:1454–1468. doi: 10.1080/21645515.2015.1129090.
    1. Gilkey MB, Moss JL, Coyne-Beasley T, Hall ME, Shah PD, Brewer NT. Physician communication about adolescent vaccination: how is human papillomavirus vaccine different? Prev Med. 2015;77:181–185. doi: 10.1016/j.ypmed.2015.05.024.
    1. Davis TC, Fredrickson DD, Arnold CL, Cross JT, Humiston SG, Green KW, et al. Childhood vaccine risk/benefit communication in private practice office settings: a national survey. Pediatrics. 2001;107:E17. doi: 10.1542/peds.107.2.e17.
    1. Dempsey AF, Lockhart S, Campagna EJ, Pyrzanowski J, Barnard J, O’Leary ST. Providers’ time spent and tools used when discussing the HPV vaccine with parents of adolescents. Vaccine. 2016;34:6217–6222. doi: 10.1016/j.vaccine.2016.10.083.
    1. Opel DJ, Robinson JD, Heritage J, Korfiatis C, Taylor JA, Mangione-Smith R. Characterizing providers' immunization communication practices during health supervision visits with vaccine-hesitant parents: a pilot study. Vaccine. 2012;30:1269–1275. doi: 10.1016/j.vaccine.2011.12.129.
    1. Henrikson NB, Opel DJ, Grothaus L, Nelson J, Scrol A, Dunn J, et al. Physician communication training and parental vaccine hesitancy: a randomized trial. Pediatrics. 2015;136:70–79. doi: 10.1542/peds.2014-3199.
    1. Opel DJ, Heritage J, Taylor JA, Mangione-Smith R, Salas HS, Devere V, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132:1037–1046. doi: 10.1542/peds.2013-2037.
    1. Opel DJ, Mangione-Smith R, Robinson JD, Heritage J, DeVere V, Salas HS, et al. The influence of provider communication behaviors on parental vaccine acceptance and visit experience. Am J Public Health. 2015;105:1998–2004. doi: 10.2105/AJPH.2014.302425.
    1. Roberto AJ, Krieger JL, Katz ML, Goei R, Jain P. Predicting pediatricians’ communication with parents about the human papillomavirus (HPV) vaccine: an application of the theory of reasoned action. Health Commun. 2011;26:303–312. doi: 10.1080/10410236.2010.550021.
    1. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211. doi: 10.1016/0749-5978(91)90020-T.
    1. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine. 2016;34:1187–1192. doi: 10.1016/j.vaccine.2016.01.023.
    1. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics. 2017;139:e20161764. doi: 10.1542/peds.2016-1764.
    1. Centers for Disease Control and Prevention. HPV vaccine information for clinicians 2016 [November 13, 2017]. Available from: . Accessed 13 Nov 2017.
    1. Perkins RB, Clark JA, Apte G, Vercruysse JL, Sumner JJ, Wall-Haas CL, et al. Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics. 2014;134:e666–e674. doi: 10.1542/peds.2014-0442.
    1. Liddon N, Michael SL, Dittus P, Markowitz LE. Maternal underestimation of child’s sexual experience: suggested implications for HPV vaccine uptake at recommended ages. J Adolesc Health. 2013;53:674–676. doi: 10.1016/j.jadohealth.2013.07.026.
    1. Malo TL, Ali KN, Sutton SK, Perkins RB, Giuliano AR, Vadaparampil ST. The content and context of physicians’ communication with males about human papillomavirus vaccination. Hum Vaccin Immunother. 2016;12:1511–1518. doi: 10.1080/21645515.2015.1132963.
    1. Williams DM, Dunsiger S. Suggestions for testing health behavior theories: implications for mediator analysis. Ann Behav Med. 2007;34:223. doi: 10.1007/BF02872677.
    1. Francis JJ, Eccles MP, Johnston M, Whitty P, Grimshaw JM, Kaner EF, et al. Explaining the effects of an intervention designed to promote evidence-based diabetes care: a theory-based process evaluation of a pragmatic cluster randomised controlled trial. Implement Sci. 2008;3:50. doi: 10.1186/1748-5908-3-50.
    1. Grimshaw JM, Presseau J, Tetroe J, Eccles MP, Francis JJ, Godin G, et al. Looking inside the black box: results of a theory-based process evaluation exploring the results of a randomized controlled trial of printed educational messages to increase primary care physicians' diabetic retinopathy referrals [trial registration number ISRCTN72772651] Implement Sci. 2014;9:86. doi: 10.1186/1748-5908-9-86.
    1. Presseau J, Grimshaw JM, Tetroe JM, Eccles MP, Francis JJ, Godin G, et al. A theory-based process evaluation alongside a randomised controlled trial of printed educational messages to increase primary care physicians' prescription of thiazide diuretics for hypertension [ISRCTN72772651] Implement Sci. 2016;11:121. doi: 10.1186/s13012-016-0485-4.
    1. Ramsay CR, Thomas RE, Croal BL, Grimshaw JM, Eccles MP. Using the theory of planned behaviour as a process evaluation tool in randomised trials of knowledge translation strategies: a case study from UK primary care. Implement Sci. 2010;5:71. doi: 10.1186/1748-5908-5-71.
    1. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Admin Pol Ment Health. 2011;38:65–76. doi: 10.1007/s10488-010-0319-7.

Source: PubMed

3
订阅